Case Description—A 12-year-old castrated male Labrador Retriever was evaluated for clinical signs associated with colorectal obstruction.
Clinical Findings—The dog had a 2-week history of tenesmus and hematochezia. On rectal examination, an annular colorectal mass was palpable extending orad into the pelvic canal. The original diagnosis of the colorectal mass was a mucosal adenoma. The dog was maintained on a low-residue diet and fecal softeners for a period of 13 months after initial diagnosis. At that time, medical management was no longer effective.
Treatment and Outcome—Placement of a colonic stent was chosen to palliate the clinical signs associated with colorectal obstruction. By use of fluoroscopic and colonoscopic guidance, a nitinol stent was placed intraluminally to open the obstructed region. Placement of the stent resulted in improvement of clinical signs, although tenesmus and obstipation occurred periodically after stent placement. At 212 days after stent placement, the patient had extensive improvement in clinical signs with minimal complications; however, clinical signs became severe at 238 days after stent placement, and the dog was euthanized. Histologic evaluation of the rectal tumor from samples obtained during necropsy revealed that the tumor had undergone malignant transformation to a carcinoma in situ.
Clinical Relevance—A stent was successfully placed in the colon and rectum to relieve obstruction associated with a tumor originally diagnosed as a benign neoplasm. Placement of colorectal stents may be an option for the palliation of colorectal obstruction secondary to neoplastic disease; however, clinical signs may persist, and continuation of medical management may be necessary.
Objective—To determine whether administration of
Crandell-Rees feline kidney (CRFK) cell lysates or vaccines
against feline viral rhinotracheitis, calicivirus,
and panleukopenia (FVRCP vaccines) that likely contain
CRFK cell proteins induces antibodies against
CRFK cell or feline renal cell (FRC) lysates in cats.
Animals—14 eight-week-old cats.
Procedure—Before and after the study, renal biopsy
specimens were obtained from each cat for histologic
evaluation. Each of 4 FVRCP vaccines was administered
to 2 cats at weeks 0, 3, 6, and 50. Between
weeks 0 and 50, another 3 pairs of cats received 11
CRFK cell lysate inoculations SC (10, 50, or 50 µg
mixed with alum). Clinicopathologic evaluations and
ELISAs to detect serum antibodies against CRFK cell
or FRC lysates were performed at intervals.
Results—Cats had no antibodies against CRFK cell
or FRC lysates initially. All cats administered CRFK
cell lysate had detectable antibodies against CRFK
cell or FRC lysates on multiple occasions. Of 6 cats
vaccinated parenterally, 5 had detectable antibodies
against CRFK cell lysate at least once, but all 6 had
detectable antibodies against FRC lysate on multiple
occasions. Cats administered an intranasal-intraocular
vaccine did not develop detectable antibodies
against either lysate. Important clinicopathologic or
histologic abnormalities were not detected during
Conclusions and Clinical Relevance—Parenteral
administration of vaccines containing viruses likely
grown on CRFK cells induced antibodies against
CRFK cell and FRC lysates in cats. Hypersensitization
with CRFK cell proteins did not result in renal disease
in cats during the 56-week study. (Am J Vet Res 2005;66:506–511)